Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β

Li Li, Eugene Y. Zhen, Rodney L. Decker, Brian A. Willis, David Waters, Peng Liu, Ann Hake, Ronald Bradley Demattos, Mosun Ayan-Oshodi

Research output: Contribution to journalArticle

Abstract

LY2599666 is a humanized, affinity-optimized monoclonal antibody antigen-binding fragment linked to a PEG molecule and targets soluble amyloid-β (Aβ) monomers. This first-in-human dose ascending study assessed pharmacokinetics (PK) (measured as serum free LY2599666 concentration) and pharmacodynamic (PD) effects (measured as plasma total soluble Aβ 40 and Aβ 42) after a single subcutaneous (SC) dose of 10, 25, 100, and 200 mg LY2599666 in healthy subjects. As LY2599666 binds to multiple soluble Aβ monomers, a two-target mediated drug disposition model (TMDD) was developed to simultaneously fit serum LY2599666 concentration and Aβ monomer levels. Four Alzheimer's disease patients completed 25 mg once-weekly dosing of LY2599666 for 12 weeks. In addition, single cerebrospinal fluid samples were collected to assess penetration capability across the blood-brain barrier. PK and PD data collected from the multiple dose cohort aligned with model predictions, suggesting the established TMDD model predicted suppression of soluble Aβ 40 and Aβ 42 in plasma after SC dosing of LY2599666.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalJournal of Alzheimer's Disease
Volume68
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Amyloid
Pharmacokinetics
Antigens
Blood-Brain Barrier
Serum
Pharmaceutical Preparations
Cerebrospinal Fluid
Healthy Volunteers
Alzheimer Disease
Monoclonal Antibodies

Keywords

  • Alzheimer's disease
  • Aβ monomer
  • pharmacokinetic/pharmacodynamic
  • target-mediated drug disposition

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β. / Li, Li; Zhen, Eugene Y.; Decker, Rodney L.; Willis, Brian A.; Waters, David; Liu, Peng; Hake, Ann; Demattos, Ronald Bradley; Ayan-Oshodi, Mosun.

In: Journal of Alzheimer's Disease, Vol. 68, No. 1, 01.01.2019, p. 137-144.

Research output: Contribution to journalArticle

Li, Li ; Zhen, Eugene Y. ; Decker, Rodney L. ; Willis, Brian A. ; Waters, David ; Liu, Peng ; Hake, Ann ; Demattos, Ronald Bradley ; Ayan-Oshodi, Mosun. / Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β. In: Journal of Alzheimer's Disease. 2019 ; Vol. 68, No. 1. pp. 137-144.
@article{0125d5bf6d2041a8a2648249488b3983,
title = "Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β",
abstract = "LY2599666 is a humanized, affinity-optimized monoclonal antibody antigen-binding fragment linked to a PEG molecule and targets soluble amyloid-β (Aβ) monomers. This first-in-human dose ascending study assessed pharmacokinetics (PK) (measured as serum free LY2599666 concentration) and pharmacodynamic (PD) effects (measured as plasma total soluble Aβ 40 and Aβ 42) after a single subcutaneous (SC) dose of 10, 25, 100, and 200 mg LY2599666 in healthy subjects. As LY2599666 binds to multiple soluble Aβ monomers, a two-target mediated drug disposition model (TMDD) was developed to simultaneously fit serum LY2599666 concentration and Aβ monomer levels. Four Alzheimer's disease patients completed 25 mg once-weekly dosing of LY2599666 for 12 weeks. In addition, single cerebrospinal fluid samples were collected to assess penetration capability across the blood-brain barrier. PK and PD data collected from the multiple dose cohort aligned with model predictions, suggesting the established TMDD model predicted suppression of soluble Aβ 40 and Aβ 42 in plasma after SC dosing of LY2599666.",
keywords = "Alzheimer's disease, Aβ monomer, pharmacokinetic/pharmacodynamic, target-mediated drug disposition",
author = "Li Li and Zhen, {Eugene Y.} and Decker, {Rodney L.} and Willis, {Brian A.} and David Waters and Peng Liu and Ann Hake and Demattos, {Ronald Bradley} and Mosun Ayan-Oshodi",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/JAD-180925",
language = "English (US)",
volume = "68",
pages = "137--144",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β

AU - Li, Li

AU - Zhen, Eugene Y.

AU - Decker, Rodney L.

AU - Willis, Brian A.

AU - Waters, David

AU - Liu, Peng

AU - Hake, Ann

AU - Demattos, Ronald Bradley

AU - Ayan-Oshodi, Mosun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - LY2599666 is a humanized, affinity-optimized monoclonal antibody antigen-binding fragment linked to a PEG molecule and targets soluble amyloid-β (Aβ) monomers. This first-in-human dose ascending study assessed pharmacokinetics (PK) (measured as serum free LY2599666 concentration) and pharmacodynamic (PD) effects (measured as plasma total soluble Aβ 40 and Aβ 42) after a single subcutaneous (SC) dose of 10, 25, 100, and 200 mg LY2599666 in healthy subjects. As LY2599666 binds to multiple soluble Aβ monomers, a two-target mediated drug disposition model (TMDD) was developed to simultaneously fit serum LY2599666 concentration and Aβ monomer levels. Four Alzheimer's disease patients completed 25 mg once-weekly dosing of LY2599666 for 12 weeks. In addition, single cerebrospinal fluid samples were collected to assess penetration capability across the blood-brain barrier. PK and PD data collected from the multiple dose cohort aligned with model predictions, suggesting the established TMDD model predicted suppression of soluble Aβ 40 and Aβ 42 in plasma after SC dosing of LY2599666.

AB - LY2599666 is a humanized, affinity-optimized monoclonal antibody antigen-binding fragment linked to a PEG molecule and targets soluble amyloid-β (Aβ) monomers. This first-in-human dose ascending study assessed pharmacokinetics (PK) (measured as serum free LY2599666 concentration) and pharmacodynamic (PD) effects (measured as plasma total soluble Aβ 40 and Aβ 42) after a single subcutaneous (SC) dose of 10, 25, 100, and 200 mg LY2599666 in healthy subjects. As LY2599666 binds to multiple soluble Aβ monomers, a two-target mediated drug disposition model (TMDD) was developed to simultaneously fit serum LY2599666 concentration and Aβ monomer levels. Four Alzheimer's disease patients completed 25 mg once-weekly dosing of LY2599666 for 12 weeks. In addition, single cerebrospinal fluid samples were collected to assess penetration capability across the blood-brain barrier. PK and PD data collected from the multiple dose cohort aligned with model predictions, suggesting the established TMDD model predicted suppression of soluble Aβ 40 and Aβ 42 in plasma after SC dosing of LY2599666.

KW - Alzheimer's disease

KW - Aβ monomer

KW - pharmacokinetic/pharmacodynamic

KW - target-mediated drug disposition

UR - http://www.scopus.com/inward/record.url?scp=85062891217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062891217&partnerID=8YFLogxK

U2 - 10.3233/JAD-180925

DO - 10.3233/JAD-180925

M3 - Article

C2 - 30741684

AN - SCOPUS:85062891217

VL - 68

SP - 137

EP - 144

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -